Reported Challenges in Health Technology Assessment of Complex Health Technologies
With complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify challenges in HTA of complex health technologies. A survey was sent to European HTA organizations participating in European Network for HTA (EUnetHTA...
Saved in:
Published in | Value in health Vol. 25; no. 6; pp. 992 - 1001 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.06.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | With complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify challenges in HTA of complex health technologies.
A survey was sent to European HTA organizations participating in European Network for HTA (EUnetHTA). The survey contained open questions and used predefined potentially complex health technologies and 7 case studies to identify types of complex health technologies and challenges faced during HTA. The survey was validated, tested for reliability by an expert panel, and pilot tested before dissemination.
A total of 22 HTA organizations completed the survey (67%). Advanced therapeutic medicinal products (ATMPs) and histology-independent therapies were considered most challenging based on the predefined complex health technologies and case studies. For the case studies, more than half of the reported challenges were “methodological,” equal in relative effectiveness assessments as in cost-effectiveness assessments. Through the open questions, we found that most of these challenges actually rooted in data unavailability. Data were reported as “absent,” “insufficient,” “immature,” or “low quality” by 18 of 20 organizations (90%), in particular data on quality of life. Policy and organizational challenges and challenges because of societal or political pressure were reported by 8 (40%) and 4 organizations (20%), respectively. Modeling issues were reported least often (n = 2, 4%).
Most challenges in HTA of complex health technologies root in data insufficiencies rather than in the complexity of health technologies itself. As the number of complex technologies grows, the urgency for new methods and policies to guide HTA decision making increases.
•In the current data-driven world, we know that also in health technology assessment (HTA) the lack of data causes major challenges. Increasingly complex health technologies may bring novel challenges for HTA, which may require new HTA methods. Previous research identified challenges for specific types of technologies, such as gene- and cell-based therapies, in limited sets of countries.•We systematically assessed the challenges experienced by HTA organizations throughout Europe for a broad set of complex health technologies. We found that reported problems expressed in methodological aspects of HTA of these technologies also often find their root in a lack of available data, rather than in the complexity of the technology itself. Health technologies that were perceived as most challenging, that is, advanced therapeutic medicinal products (ATMPs) and histology-independent therapies, inherently create new difficulties in evidence generation.•HTA organizations report many challenges when assessing complex health technologies. Nevertheless, our results show that many of these challenges originate from a lack of data rather than from the complexity of the technology itself. As the development of these complex technologies continues to grow, the need to find a solution for lacking (quality) data increases in importance. Future research that attempts to improve data quality could focus on the alignment of clinical data generation with evidentiary requirements for subsequent stakeholders for future technologies early in the development process. |
---|---|
AbstractList | With complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify challenges in HTA of complex health technologies.
A survey was sent to European HTA organizations participating in European Network for HTA (EUnetHTA). The survey contained open questions and used predefined potentially complex health technologies and 7 case studies to identify types of complex health technologies and challenges faced during HTA. The survey was validated, tested for reliability by an expert panel, and pilot tested before dissemination.
A total of 22 HTA organizations completed the survey (67%). Advanced therapeutic medicinal products (ATMPs) and histology-independent therapies were considered most challenging based on the predefined complex health technologies and case studies. For the case studies, more than half of the reported challenges were “methodological,” equal in relative effectiveness assessments as in cost-effectiveness assessments. Through the open questions, we found that most of these challenges actually rooted in data unavailability. Data were reported as “absent,” “insufficient,” “immature,” or “low quality” by 18 of 20 organizations (90%), in particular data on quality of life. Policy and organizational challenges and challenges because of societal or political pressure were reported by 8 (40%) and 4 organizations (20%), respectively. Modeling issues were reported least often (n = 2, 4%).
Most challenges in HTA of complex health technologies root in data insufficiencies rather than in the complexity of health technologies itself. As the number of complex technologies grows, the urgency for new methods and policies to guide HTA decision making increases.
•In the current data-driven world, we know that also in health technology assessment (HTA) the lack of data causes major challenges. Increasingly complex health technologies may bring novel challenges for HTA, which may require new HTA methods. Previous research identified challenges for specific types of technologies, such as gene- and cell-based therapies, in limited sets of countries.•We systematically assessed the challenges experienced by HTA organizations throughout Europe for a broad set of complex health technologies. We found that reported problems expressed in methodological aspects of HTA of these technologies also often find their root in a lack of available data, rather than in the complexity of the technology itself. Health technologies that were perceived as most challenging, that is, advanced therapeutic medicinal products (ATMPs) and histology-independent therapies, inherently create new difficulties in evidence generation.•HTA organizations report many challenges when assessing complex health technologies. Nevertheless, our results show that many of these challenges originate from a lack of data rather than from the complexity of the technology itself. As the development of these complex technologies continues to grow, the need to find a solution for lacking (quality) data increases in importance. Future research that attempts to improve data quality could focus on the alignment of clinical data generation with evidentiary requirements for subsequent stakeholders for future technologies early in the development process. With complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify challenges in HTA of complex health technologies. A survey was sent to European HTA organizations participating in European Network for HTA (EUnetHTA). The survey contained open questions and used predefined potentially complex health technologies and 7 case studies to identify types of complex health technologies and challenges faced during HTA. The survey was validated, tested for reliability by an expert panel, and pilot tested before dissemination. A total of 22 HTA organizations completed the survey (67%). Advanced therapeutic medicinal products (ATMPs) and histology-independent therapies were considered most challenging based on the predefined complex health technologies and case studies. For the case studies, more than half of the reported challenges were "methodological," equal in relative effectiveness assessments as in cost-effectiveness assessments. Through the open questions, we found that most of these challenges actually rooted in data unavailability. Data were reported as "absent," "insufficient," "immature," or "low quality" by 18 of 20 organizations (90%), in particular data on quality of life. Policy and organizational challenges and challenges because of societal or political pressure were reported by 8 (40%) and 4 organizations (20%), respectively. Modeling issues were reported least often (n = 2, 4%). Most challenges in HTA of complex health technologies root in data insufficiencies rather than in the complexity of health technologies itself. As the number of complex technologies grows, the urgency for new methods and policies to guide HTA decision making increases. OBJECTIVESWith complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify challenges in HTA of complex health technologies. METHODSA survey was sent to European HTA organizations participating in European Network for HTA (EUnetHTA). The survey contained open questions and used predefined potentially complex health technologies and 7 case studies to identify types of complex health technologies and challenges faced during HTA. The survey was validated, tested for reliability by an expert panel, and pilot tested before dissemination. RESULTSA total of 22 HTA organizations completed the survey (67%). Advanced therapeutic medicinal products (ATMPs) and histology-independent therapies were considered most challenging based on the predefined complex health technologies and case studies. For the case studies, more than half of the reported challenges were "methodological," equal in relative effectiveness assessments as in cost-effectiveness assessments. Through the open questions, we found that most of these challenges actually rooted in data unavailability. Data were reported as "absent," "insufficient," "immature," or "low quality" by 18 of 20 organizations (90%), in particular data on quality of life. Policy and organizational challenges and challenges because of societal or political pressure were reported by 8 (40%) and 4 organizations (20%), respectively. Modeling issues were reported least often (n = 2, 4%). CONCLUSIONSMost challenges in HTA of complex health technologies root in data insufficiencies rather than in the complexity of health technologies itself. As the number of complex technologies grows, the urgency for new methods and policies to guide HTA decision making increases. |
Author | Hogervorst, Milou A. Mantel-Teeuwisse, Aukje K. Goettsch, Wim G. Vreman, Rick A. |
Author_xml | – sequence: 1 givenname: Milou A. surname: Hogervorst fullname: Hogervorst, Milou A. organization: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands – sequence: 2 givenname: Rick A. surname: Vreman fullname: Vreman, Rick A. organization: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands – sequence: 3 givenname: Aukje K. surname: Mantel-Teeuwisse fullname: Mantel-Teeuwisse, Aukje K. organization: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands – sequence: 4 givenname: Wim G. surname: Goettsch fullname: Goettsch, Wim G. email: w.g.goettsch@uu.nl organization: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35667787$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1Lw0AQhhep2A_9BYLk6CV1v7KbHDyUolYQhFLPS7I7aRM22ZpNi_33bmn1IggDM4fnnWGeMRq0rgWEbgmeEkzEQz2t97mdUkzJlIRiibhAI5JQHnPJ2CDMOEtjhkkyRGPva4yxYDS5QsOACilTOULLJWxd14OJ5pvcWmjX4KOqjRaQ234TrUBvWmfd-hDNvAfvG2j7yJXR3DVbC19_uAr8Nbosc-vh5twn6OP5aTVfxG_vL6_z2VusOeZ9LBNeCFNwwwVoSjMoSs4ynBbMkBQSSUuGc5MUtJA8BcCSlAIoaEjTLDWJYRN0f9q77dznDnyvmsprsDZvwe28okJyjKmgIqDshOrOed9BqbZd1eTdQRGsjjJVrY4y1VGmIqGCoZC6Ox_YFQ2Y38yPvQA8ngAIb-4r6JTXFbQaTNWB7pVx1b8HvgGguYhH |
CitedBy_id | crossref_primary_10_1136_bmjopen_2023_072309 crossref_primary_10_3390_curroncol29080455 crossref_primary_10_1017_S0266462324000060 crossref_primary_10_1111_hex_13697 crossref_primary_10_1007_s41669_024_00477_8 crossref_primary_10_1017_S0266462323002696 crossref_primary_10_1017_S0266462323000375 crossref_primary_10_1097_PXH_0000000000000026 crossref_primary_10_1016_j_drudis_2024_104031 crossref_primary_10_57264_cer_2023_0145 |
Cites_doi | 10.1111/bjd.16140 10.3390/ijerph17228309 10.2146/ajhp070364 10.1080/00365513.2016.1206437 10.1159/000446537 10.1016/j.drudis.2020.04.012 10.1016/j.jval.2019.09.2199 10.1136/bmj.l6435 10.1177/0272989X17725740 10.1111/bcp.14275 10.1007/s40273-020-00887-6 10.1080/10428194.2017.1390230 10.1016/S0140-6736(19)30037-6 10.1017/S0266462319000825 10.1016/S0140-6736(19)33178-2 10.1017/S0266462320000215 10.1186/s12874-020-01145-1 10.1007/s40273-017-0596-z 10.1017/S0266462309990638 10.4103/1117-1936.173959 10.1016/j.jval.2020.04.1833 10.1016/j.ctrv.2019.01.001 10.2214/ajr.149.6.1127 10.1038/s41416-019-0653-9 10.1002/cpt.1251 10.1016/j.jval.2016.03.1723 10.1007/s10198-018-1007-x 10.1371/journal.pone.0146262 10.1038/d41586-020-02679-6 10.1016/S0140-6736(15)61478-7 10.1002/sim.9034 10.1016/j.jval.2019.12.008 10.1016/j.healthpol.2017.03.009 10.1007/s10198-020-01212-w 10.1002/cpt.1835 10.1186/s13023-020-01462-0 |
ContentType | Journal Article |
Copyright | 2021 ISPOR - The professional society for health economics and outcomes research Copyright © 2021 ISPOR - The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2021 ISPOR - The professional society for health economics and outcomes research – notice: Copyright © 2021 ISPOR - The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.jval.2021.11.1356 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1524-4733 |
EndPage | 1001 |
ExternalDocumentID | 10_1016_j_jval_2021_11_1356 35667787 S1098301521031879 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6I. 6PF 7-5 7PT 8-1 8P~ 8UM AACTN AAEDT AAEDW AAFJI AAFTH AAFWJ AAHHS AAIAV AAIKJ AAKOC AALRI AAOAW AAPFB AAQFI AAQXK AAWTL AAXUO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABLVK ABMAC ABMMH ABMZM ABVKL ABXDB ABYKQ ACCFJ ACDAQ ACGFS ACHQT ACPRK ACRLP ACXQS ADBBV ADEZE ADFHU ADMUD AEBSH AEEZP AEKER AENEX AEQDE AEVXI AEXQZ AEYQN AFBPY AFCTW AFEBI AFKWA AFRHN AFTJW AFXIZ AFZJQ AGHFR AGTHC AGUBO AGYEJ AIEXJ AIIAU AIKHN AITUG AIWBW AJAOE AJBDE AJBFU AJOXV AJRQY AJUYK AKYCK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AOMHK ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFLBG EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB IXIXF KOM LCYCR M41 MO0 N9A NCXOZ O-L O9- OAUVE OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- RIG ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SUPJJ SV3 T5K TEORI TUS W99 WYUIH XG1 YFH Z5R ~G- 0SF AAXKI ADVLN AFJKZ AKRWK NPM OIG AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c404t-754b6db4d46ec229ebf43908b3d18e572f30ad5b2b748ee071f6e2ece8898d5d3 |
IEDL.DBID | IXB |
ISSN | 1098-3015 |
IngestDate | Fri Aug 16 08:29:17 EDT 2024 Thu Sep 26 16:17:29 EDT 2024 Sat Sep 28 08:20:02 EDT 2024 Fri Feb 23 02:40:11 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | health technology assessment data quality personalized health technologies challenges decision making cost-effectiveness assessment relative effectiveness assessment |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2021 ISPOR - The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c404t-754b6db4d46ec229ebf43908b3d18e572f30ad5b2b748ee071f6e2ece8898d5d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1098301521031879 |
PMID | 35667787 |
PQID | 2674002626 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2674002626 crossref_primary_10_1016_j_jval_2021_11_1356 pubmed_primary_35667787 elsevier_sciencedirect_doi_10_1016_j_jval_2021_11_1356 |
PublicationCentury | 2000 |
PublicationDate | June 2022 2022-Jun 2022-06-00 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Value in health |
PublicationTitleAlternate | Value Health |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Nicod, Whittal, Drummond, Facey (bib9) 2020; 15 Vreman, Naci, Goettsch (bib17) 2020; 108 Jönsson, Hampson, Michaels, Towse, von der Schulenburg, Wong (bib11) 2019; 20 bib34 Thom, Jugl, Palaka, Jawla (bib50) 2016; 19 bib35 Dabbous, Chachoua, Caban, Toumi (bib54) 2020; 23 Berm, Looff, Wilffert (bib24) 2016; 11 Ten Ham, Klungel, Leufkens, Frederix (bib25) 2020; 23 bib29 Bolarinwa (bib31) 2015; 22 Chen, Staton, Ayer, Goldstein, Koff, Flowers (bib27) 2018; 59 Higgins, Welton (bib48) 2015; 386 Naci, Salcher-Konrad, Kesselheim (bib40) 2020; 395 Häggman-Henrikson, Alstergren, Davidson (bib47) Larson, Walker, Parow (bib6) Vreman, Broekhoff, Leufkens, Mantel-Teeuwisse, Goettsch (bib55) 2020; 17 Phillippo, Ades, Dias, Palmer, Abrams, Welton (bib46) 2018; 38 Verweij, Hendriks, Zwierzina (bib39) 2019; 74 Chalkou, Steyerberg, Egger, Manca, Pellegrini, Salanti (bib43) 2021; 40 Lloyd-Williams, Hughes (bib26) 2021; 87 Chamova (bib37) Cooper, Bouvy, Baker (bib12) 2020; 368 bib41 bib42 Collins, Moons (bib51) 2019; 393 Jönsson, Oortwijn, Rutten, Wailoo (bib53) October 2015 bib3 Kimberlin, Winterstein (bib32) 2008; 65 bib2 O’Rourke, Werkö, Merlin, Huang, Schuller (bib38) 2020; 36 Venkitachalam (bib30) Warren, Brnabic, Saure (bib49) 2017; 178 Photopoulos (bib13) 2020; 585 Pooley, Marjenberg, Embleton, Langham (bib45) 2019; 22 Nicod, Annemans, Bucsics, Lee, Upadhyaya, Facey (bib8) 2019; 123 Ghabri, Lam, Bocquet, Spath (bib23) 2020; 38 Pruce, Michel, Theocharous (bib7) bib14 Abrams, Hessel (bib21) 1987; 149 Leyens, Brand (bib15) 2016; 19 Lampe, Mäkelä, Garrido (bib36) 2009; 25 Jacobzone (bib4) Vreman, Bouvy, Bloem (bib16) 2019; 105 Blagden, Billingham, Brown (bib5) 2020; 122 Schmitz (bib33) Doble (bib28) 2016; 245 Panch, Szolovits, Atun (bib52) 2018; 8 bib22 Rekkas, Paulus, Raman (bib44) 2020; 20 Coyle, Durand-Zaleski, Farrington (bib10) 2020; 21 bib19 O’Rourke, Oortwijn, Schuller (bib1) 2020; 36 Makady, van Veelen, Jonsson (bib20) 2018; 36 Vreman, de Ruijter, Zawada (bib18) 2020; 25 Naci (10.1016/j.jval.2021.11.1356_bib40) 2020; 395 Leyens (10.1016/j.jval.2021.11.1356_bib15) 2016; 19 Verweij (10.1016/j.jval.2021.11.1356_bib39) 2019; 74 Berm (10.1016/j.jval.2021.11.1356_bib24) 2016; 11 Blagden (10.1016/j.jval.2021.11.1356_bib5) 2020; 122 Doble (10.1016/j.jval.2021.11.1356_bib28) 2016; 245 Bolarinwa (10.1016/j.jval.2021.11.1356_bib31) 2015; 22 Chalkou (10.1016/j.jval.2021.11.1356_bib43) 2021; 40 Makady (10.1016/j.jval.2021.11.1356_bib20) 2018; 36 Chamova (10.1016/j.jval.2021.11.1356_bib37) Vreman (10.1016/j.jval.2021.11.1356_bib17) 2020; 108 Panch (10.1016/j.jval.2021.11.1356_bib52) 2018; 8 O’Rourke (10.1016/j.jval.2021.11.1356_bib38) 2020; 36 Venkitachalam (10.1016/j.jval.2021.11.1356_bib30) Photopoulos (10.1016/j.jval.2021.11.1356_bib13) 2020; 585 Nicod (10.1016/j.jval.2021.11.1356_bib9) 2020; 15 Abrams (10.1016/j.jval.2021.11.1356_bib21) 1987; 149 Schmitz (10.1016/j.jval.2021.11.1356_bib33) Rekkas (10.1016/j.jval.2021.11.1356_bib44) 2020; 20 Phillippo (10.1016/j.jval.2021.11.1356_bib46) 2018; 38 Lampe (10.1016/j.jval.2021.11.1356_bib36) 2009; 25 Jönsson (10.1016/j.jval.2021.11.1356_bib53) 2015 Lloyd-Williams (10.1016/j.jval.2021.11.1356_bib26) 2021; 87 O’Rourke (10.1016/j.jval.2021.11.1356_bib1) 2020; 36 Pruce (10.1016/j.jval.2021.11.1356_bib7) Nicod (10.1016/j.jval.2021.11.1356_bib8) 2019; 123 Vreman (10.1016/j.jval.2021.11.1356_bib18) 2020; 25 Vreman (10.1016/j.jval.2021.11.1356_bib16) 2019; 105 Coyle (10.1016/j.jval.2021.11.1356_bib10) 2020; 21 Collins (10.1016/j.jval.2021.11.1356_bib51) 2019; 393 Vreman (10.1016/j.jval.2021.11.1356_bib55) 2020; 17 Cooper (10.1016/j.jval.2021.11.1356_bib12) 2020; 368 Larson (10.1016/j.jval.2021.11.1356_bib6) Häggman-Henrikson (10.1016/j.jval.2021.11.1356_bib47) Warren (10.1016/j.jval.2021.11.1356_bib49) 2017; 178 Dabbous (10.1016/j.jval.2021.11.1356_bib54) 2020; 23 Jacobzone (10.1016/j.jval.2021.11.1356_bib4) Higgins (10.1016/j.jval.2021.11.1356_bib48) 2015; 386 Ten Ham (10.1016/j.jval.2021.11.1356_bib25) 2020; 23 Chen (10.1016/j.jval.2021.11.1356_bib27) 2018; 59 Jönsson (10.1016/j.jval.2021.11.1356_bib11) 2019; 20 Pooley (10.1016/j.jval.2021.11.1356_bib45) 2019; 22 Thom (10.1016/j.jval.2021.11.1356_bib50) 2016; 19 Kimberlin (10.1016/j.jval.2021.11.1356_bib32) 2008; 65 Ghabri (10.1016/j.jval.2021.11.1356_bib23) 2020; 38 |
References_xml | – volume: 8 year: 2018 ident: bib52 article-title: Artificial intelligence, machine learning and health systems publication-title: J Glob Health contributor: fullname: Atun – volume: 105 start-page: 684 year: 2019 end-page: 691 ident: bib16 article-title: Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs publication-title: Clin Pharmacol Ther contributor: fullname: Bloem – volume: 38 start-page: 459 year: 2020 end-page: 471 ident: bib23 article-title: Systematic literature review of economic evaluations of biological treatment sequences for patients with moderate to severe rheumatoid arthritis previously treated with disease-modifying anti-rheumatic drugs publication-title: Pharmacoeconomics contributor: fullname: Spath – ident: bib35 article-title: Nvivo: NVivo qualitative data analysis software. QSR International – ident: bib30 article-title: Validity and reliability of questionnaires. Slideshare contributor: fullname: Venkitachalam – ident: bib34 article-title: Microsoft Excel, spreadsheet software, excel free trial – volume: 108 start-page: 350 year: 2020 end-page: 357 ident: bib17 article-title: Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe publication-title: Clin Pharmacol Ther contributor: fullname: Goettsch – ident: bib47 article-title: Pharmacological treatment of oro-facial pain – health technology assessment including a systematic review with network meta-analysis. Wiley Online Library contributor: fullname: Davidson – ident: bib2 article-title: JA WP5 – relative effectiveness assessment of pharmaceuticals. EUnetHTA – ident: bib41 article-title: Parallel consultation with regulators and health technology assessment bodies. European Medicines Agency – ident: bib42 article-title: EMA and EUnetHTA step up interaction to align data requirements. European Medicines Agency – volume: 36 start-page: 359 year: 2018 end-page: 368 ident: bib20 article-title: Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies publication-title: Pharmacoeconomics contributor: fullname: Jonsson – ident: bib7 article-title: Do payers find value in innovative trial designs? The Evidence Form contributor: fullname: Theocharous – volume: 20 start-page: 427 year: 2019 end-page: 438 ident: bib11 article-title: Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare publication-title: Eur J Health Econ contributor: fullname: Wong – ident: bib14 article-title: Larotrectinib for treating NTRK fusion-positive solid tumours: overview. NICE – volume: 393 start-page: 1577 year: 2019 end-page: 1579 ident: bib51 article-title: Reporting of artificial intelligence prediction models publication-title: Lancet contributor: fullname: Moons – volume: 15 start-page: 189 year: 2020 ident: bib9 article-title: Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches publication-title: Orphanet J Rare Dis contributor: fullname: Facey – ident: bib37 article-title: Mapping of HTA national organizations, programmes and processes in EU and Norway. Publication Office of the European Union contributor: fullname: Chamova – volume: 25 start-page: 1223 year: 2020 end-page: 1231 ident: bib18 article-title: Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations publication-title: Drug Discov Today contributor: fullname: Zawada – volume: 23 start-page: 425 year: 2020 end-page: 433 ident: bib54 article-title: Managed entry agreements: policy analysis from the European perspective publication-title: Value Health contributor: fullname: Toumi – volume: 59 start-page: 1700 year: 2018 end-page: 1709 ident: bib27 article-title: Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma publication-title: Leuk Lymphoma contributor: fullname: Flowers – volume: 149 start-page: 1127 year: 1987 end-page: 1132 ident: bib21 article-title: Health technology assessment: problems and challenges publication-title: AJR Am J Roentgenol contributor: fullname: Hessel – volume: 19 start-page: A100 year: 2016 end-page: A101 ident: bib50 article-title: PRM167 Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals publication-title: Value Health contributor: fullname: Jawla – volume: 25 start-page: 9 year: 2009 end-page: 20 ident: bib36 article-title: The HTA Core Model: a novel method for producing and reporting health technology assessments publication-title: Int J Technol Assess Health Care contributor: fullname: Garrido – volume: 17 start-page: 8309 year: 2020 ident: bib55 article-title: Application of managed entry agreements for innovative therapies in different settings and combinations: a feasibility analysis publication-title: Int J Environ Res Public Health contributor: fullname: Goettsch – volume: 40 start-page: 4362 year: 2021 end-page: 4375 ident: bib43 article-title: A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for Multiple Sclerosis publication-title: Stat Med contributor: fullname: Salanti – volume: 74 start-page: 15 year: 2019 end-page: 20 ident: bib39 article-title: Innovation in oncology clinical trial design publication-title: Cancer Treat Rev contributor: fullname: Zwierzina – ident: bib4 article-title: Healthy ageing and the challenges of new technologies: can OECD social and health-care systems provide for the future? OECD contributor: fullname: Jacobzone – ident: bib22 article-title: Reviewing our methods for health technology evaluation: consultation | NICE guidance | Our programmes | What we do | About. NICE – volume: 123 start-page: 140 year: 2019 end-page: 151 ident: bib8 article-title: HTA program response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries publication-title: Health Policy contributor: fullname: Facey – volume: 36 start-page: 1 year: 2020 end-page: 4 ident: bib38 article-title: The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint publication-title: Int J Technol Assess Health Care contributor: fullname: Schuller – volume: 178 start-page: 1064 year: 2017 end-page: 1071 ident: bib49 article-title: Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab publication-title: Br J Dermatol contributor: fullname: Saure – volume: 23 start-page: 1268 year: 2020 end-page: 1280 ident: bib25 article-title: A review of methodological considerations for economic evaluations of gene therapies and their application in literature publication-title: Value Health contributor: fullname: Frederix – volume: 21 start-page: 1421 year: 2020 end-page: 1437 ident: bib10 article-title: HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies publication-title: Eur J Health Econ contributor: fullname: Farrington – volume: 87 start-page: 2428 year: 2021 end-page: 2443 ident: bib26 article-title: A systematic review of economic evaluations of advanced therapy medicinal products publication-title: Br J Clin Pharmacol contributor: fullname: Hughes – volume: 122 start-page: 473 year: 2020 end-page: 482 ident: bib5 article-title: Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement publication-title: Br J Cancer contributor: fullname: Brown – ident: bib19 article-title: R-L Data in drug. Development. IMI GetReal initiative. GetReal – volume: 395 start-page: 986 year: 2020 end-page: 997 ident: bib40 article-title: Generating comparative evidence on new drugs and devices before approval [published correction appears in publication-title: Lancet contributor: fullname: Kesselheim – ident: bib3 article-title: HTx project: next generation health technology assessment. HTx – volume: 386 start-page: 628 year: 2015 end-page: 630 ident: bib48 article-title: Network meta-analysis: a norm for comparative effectiveness? publication-title: Lancet contributor: fullname: Welton – volume: 22 start-page: S814 year: 2019 ident: bib45 article-title: PNS299 the increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) Health Technology Assessment (HTA) submission process publication-title: Value Health contributor: fullname: Langham – volume: 38 start-page: 200 year: 2018 end-page: 211 ident: bib46 article-title: Methods for population-adjusted indirect comparisons in health technology appraisal publication-title: Med Decis Making contributor: fullname: Welton – volume: 65 start-page: 2276 year: 2008 end-page: 2284 ident: bib32 article-title: Validity and reliability of measurement instruments used in research publication-title: Am J Health Syst Pharm contributor: fullname: Winterstein – volume: 19 start-page: 187 year: 2016 end-page: 191 ident: bib15 article-title: Early patient access to medicines: health technology assessment bodies need to catch up with new marketing authorization methods publication-title: Public Health Genomics contributor: fullname: Brand – ident: bib6 article-title: Innovative clinical trial designs Welcomed by regulators but what about the payers? ISPOR Glasgow contributor: fullname: Parow – volume: 22 start-page: 195 year: 2015 end-page: 201 ident: bib31 article-title: Principles and methods of validity and reliability testing of questionnaires used in social and health science researches publication-title: Niger Postgrad Med J contributor: fullname: Bolarinwa – volume: 36 start-page: 187 year: 2020 end-page: 190 ident: bib1 article-title: The new definition of health technology assessment: a milestone in international collaboration publication-title: Int J Technol Assess Health Care contributor: fullname: Schuller – ident: bib29 article-title: An analysis of HTA and reimbursement procedures in EUnetHTA partner countries [final report]. EUnetHTA – volume: 20 start-page: 264 year: 2020 ident: bib44 article-title: Predictive approaches to heterogeneous treatment effects: a scoping review publication-title: BMC Med Res Methodol contributor: fullname: Raman – volume: 11 year: 2016 ident: bib24 article-title: Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature publication-title: PLoS One contributor: fullname: Wilffert – year: October 2015 ident: bib53 article-title: Health technology assessment methodology programme review of external evaluation committee contributor: fullname: Wailoo – volume: 368 start-page: l6435 year: 2020 ident: bib12 article-title: How should we assess the clinical and cost effectiveness of histology independent cancer drugs? publication-title: BMJ contributor: fullname: Baker – volume: 585 start-page: S16 year: 2020 end-page: S18 ident: bib13 article-title: The future of tissue-agnostic drugs publication-title: Nature contributor: fullname: Photopoulos – volume: 245 start-page: S6 year: 2016 end-page: S11 ident: bib28 article-title: Budget impact and cost-effectiveness: can we afford precision medicine in oncology? publication-title: Scand J Clin Lab Invest Suppl contributor: fullname: Doble – ident: bib33 article-title: LimeSurvey - the free & open source survey software tool! LimeSurvey contributor: fullname: Schmitz – volume: 178 start-page: 1064 issue: 5 year: 2017 ident: 10.1016/j.jval.2021.11.1356_bib49 article-title: Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab publication-title: Br J Dermatol doi: 10.1111/bjd.16140 contributor: fullname: Warren – volume: 8 issue: 2 year: 2018 ident: 10.1016/j.jval.2021.11.1356_bib52 article-title: Artificial intelligence, machine learning and health systems publication-title: J Glob Health contributor: fullname: Panch – volume: 17 start-page: 8309 issue: 22 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib55 article-title: Application of managed entry agreements for innovative therapies in different settings and combinations: a feasibility analysis publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph17228309 contributor: fullname: Vreman – volume: 65 start-page: 2276 issue: 23 year: 2008 ident: 10.1016/j.jval.2021.11.1356_bib32 article-title: Validity and reliability of measurement instruments used in research publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp070364 contributor: fullname: Kimberlin – volume: 245 start-page: S6 year: 2016 ident: 10.1016/j.jval.2021.11.1356_bib28 article-title: Budget impact and cost-effectiveness: can we afford precision medicine in oncology? publication-title: Scand J Clin Lab Invest Suppl doi: 10.1080/00365513.2016.1206437 contributor: fullname: Doble – ident: 10.1016/j.jval.2021.11.1356_bib33 contributor: fullname: Schmitz – volume: 19 start-page: 187 issue: 3 year: 2016 ident: 10.1016/j.jval.2021.11.1356_bib15 article-title: Early patient access to medicines: health technology assessment bodies need to catch up with new marketing authorization methods publication-title: Public Health Genomics doi: 10.1159/000446537 contributor: fullname: Leyens – volume: 25 start-page: 1223 issue: 7 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib18 article-title: Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations publication-title: Drug Discov Today doi: 10.1016/j.drudis.2020.04.012 contributor: fullname: Vreman – volume: 22 start-page: S814 issue: suppl 3 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib45 article-title: PNS299 the increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) Health Technology Assessment (HTA) submission process publication-title: Value Health doi: 10.1016/j.jval.2019.09.2199 contributor: fullname: Pooley – volume: 368 start-page: l6435 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib12 article-title: How should we assess the clinical and cost effectiveness of histology independent cancer drugs? publication-title: BMJ doi: 10.1136/bmj.l6435 contributor: fullname: Cooper – volume: 38 start-page: 200 issue: 2 year: 2018 ident: 10.1016/j.jval.2021.11.1356_bib46 article-title: Methods for population-adjusted indirect comparisons in health technology appraisal publication-title: Med Decis Making doi: 10.1177/0272989X17725740 contributor: fullname: Phillippo – volume: 87 start-page: 2428 issue: 6 year: 2021 ident: 10.1016/j.jval.2021.11.1356_bib26 article-title: A systematic review of economic evaluations of advanced therapy medicinal products publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14275 contributor: fullname: Lloyd-Williams – volume: 38 start-page: 459 issue: 5 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib23 article-title: Systematic literature review of economic evaluations of biological treatment sequences for patients with moderate to severe rheumatoid arthritis previously treated with disease-modifying anti-rheumatic drugs publication-title: Pharmacoeconomics doi: 10.1007/s40273-020-00887-6 contributor: fullname: Ghabri – volume: 59 start-page: 1700 issue: 7 year: 2018 ident: 10.1016/j.jval.2021.11.1356_bib27 article-title: Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma publication-title: Leuk Lymphoma doi: 10.1080/10428194.2017.1390230 contributor: fullname: Chen – volume: 393 start-page: 1577 issue: 10181 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib51 article-title: Reporting of artificial intelligence prediction models publication-title: Lancet doi: 10.1016/S0140-6736(19)30037-6 contributor: fullname: Collins – volume: 36 start-page: 1 issue: 1 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib38 article-title: The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462319000825 contributor: fullname: O’Rourke – volume: 395 start-page: 986 issue: 10228 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib40 article-title: Generating comparative evidence on new drugs and devices before approval [published correction appears in Lancet. 2020;395(10242):1972] publication-title: Lancet doi: 10.1016/S0140-6736(19)33178-2 contributor: fullname: Naci – volume: 36 start-page: 187 issue: 3 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib1 article-title: The new definition of health technology assessment: a milestone in international collaboration publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462320000215 contributor: fullname: O’Rourke – volume: 20 start-page: 264 issue: 1 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib44 article-title: Predictive approaches to heterogeneous treatment effects: a scoping review publication-title: BMC Med Res Methodol doi: 10.1186/s12874-020-01145-1 contributor: fullname: Rekkas – volume: 36 start-page: 359 issue: 3 year: 2018 ident: 10.1016/j.jval.2021.11.1356_bib20 article-title: Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies publication-title: Pharmacoeconomics doi: 10.1007/s40273-017-0596-z contributor: fullname: Makady – year: 2015 ident: 10.1016/j.jval.2021.11.1356_bib53 contributor: fullname: Jönsson – volume: 25 start-page: 9 issue: suppl 2 year: 2009 ident: 10.1016/j.jval.2021.11.1356_bib36 article-title: The HTA Core Model: a novel method for producing and reporting health technology assessments publication-title: Int J Technol Assess Health Care doi: 10.1017/S0266462309990638 contributor: fullname: Lampe – ident: 10.1016/j.jval.2021.11.1356_bib7 contributor: fullname: Pruce – volume: 22 start-page: 195 issue: 4 year: 2015 ident: 10.1016/j.jval.2021.11.1356_bib31 article-title: Principles and methods of validity and reliability testing of questionnaires used in social and health science researches publication-title: Niger Postgrad Med J doi: 10.4103/1117-1936.173959 contributor: fullname: Bolarinwa – volume: 23 start-page: 1268 issue: 9 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib25 article-title: A review of methodological considerations for economic evaluations of gene therapies and their application in literature publication-title: Value Health doi: 10.1016/j.jval.2020.04.1833 contributor: fullname: Ten Ham – ident: 10.1016/j.jval.2021.11.1356_bib6 contributor: fullname: Larson – volume: 74 start-page: 15 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib39 article-title: Innovation in oncology clinical trial design publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2019.01.001 contributor: fullname: Verweij – ident: 10.1016/j.jval.2021.11.1356_bib37 contributor: fullname: Chamova – volume: 149 start-page: 1127 issue: 6 year: 1987 ident: 10.1016/j.jval.2021.11.1356_bib21 article-title: Health technology assessment: problems and challenges publication-title: AJR Am J Roentgenol doi: 10.2214/ajr.149.6.1127 contributor: fullname: Abrams – volume: 122 start-page: 473 issue: 4 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib5 article-title: Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement publication-title: Br J Cancer doi: 10.1038/s41416-019-0653-9 contributor: fullname: Blagden – ident: 10.1016/j.jval.2021.11.1356_bib30 contributor: fullname: Venkitachalam – volume: 105 start-page: 684 issue: 3 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib16 article-title: Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1251 contributor: fullname: Vreman – volume: 19 start-page: A100 issue: 3 year: 2016 ident: 10.1016/j.jval.2021.11.1356_bib50 article-title: PRM167 Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals publication-title: Value Health doi: 10.1016/j.jval.2016.03.1723 contributor: fullname: Thom – volume: 20 start-page: 427 issue: 3 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib11 article-title: Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare publication-title: Eur J Health Econ doi: 10.1007/s10198-018-1007-x contributor: fullname: Jönsson – volume: 11 issue: 1 year: 2016 ident: 10.1016/j.jval.2021.11.1356_bib24 article-title: Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature publication-title: PLoS One doi: 10.1371/journal.pone.0146262 contributor: fullname: Berm – volume: 585 start-page: S16 issue: 7826 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib13 article-title: The future of tissue-agnostic drugs publication-title: Nature doi: 10.1038/d41586-020-02679-6 contributor: fullname: Photopoulos – volume: 386 start-page: 628 issue: 9994 year: 2015 ident: 10.1016/j.jval.2021.11.1356_bib48 article-title: Network meta-analysis: a norm for comparative effectiveness? publication-title: Lancet doi: 10.1016/S0140-6736(15)61478-7 contributor: fullname: Higgins – ident: 10.1016/j.jval.2021.11.1356_bib47 contributor: fullname: Häggman-Henrikson – volume: 40 start-page: 4362 issue: 20 year: 2021 ident: 10.1016/j.jval.2021.11.1356_bib43 article-title: A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for Multiple Sclerosis publication-title: Stat Med doi: 10.1002/sim.9034 contributor: fullname: Chalkou – volume: 23 start-page: 425 issue: 4 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib54 article-title: Managed entry agreements: policy analysis from the European perspective publication-title: Value Health doi: 10.1016/j.jval.2019.12.008 contributor: fullname: Dabbous – volume: 123 start-page: 140 issue: 2 year: 2019 ident: 10.1016/j.jval.2021.11.1356_bib8 article-title: HTA program response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries publication-title: Health Policy doi: 10.1016/j.healthpol.2017.03.009 contributor: fullname: Nicod – ident: 10.1016/j.jval.2021.11.1356_bib4 contributor: fullname: Jacobzone – volume: 21 start-page: 1421 issue: 9 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib10 article-title: HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies publication-title: Eur J Health Econ doi: 10.1007/s10198-020-01212-w contributor: fullname: Coyle – volume: 108 start-page: 350 issue: 2 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib17 article-title: Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1835 contributor: fullname: Vreman – volume: 15 start-page: 189 issue: 1 year: 2020 ident: 10.1016/j.jval.2021.11.1356_bib9 article-title: Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-020-01462-0 contributor: fullname: Nicod |
SSID | ssj0006325 |
Score | 2.436396 |
Snippet | With complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to identify... OBJECTIVESWith complex health technologies entering the market, methods for health technology assessment (HTA) may require changes. This study aimed to... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 992 |
SubjectTerms | challenges cost-effectiveness assessment data quality decision making health technology assessment personalized health technologies relative effectiveness assessment |
Title | Reported Challenges in Health Technology Assessment of Complex Health Technologies |
URI | https://dx.doi.org/10.1016/j.jval.2021.11.1356 https://www.ncbi.nlm.nih.gov/pubmed/35667787 https://search.proquest.com/docview/2674002626 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La-MwEB76gNJL6fsdVFh6ihtb1svHNGxJ220p3bbkJiJLhoTilCaB5tLfXo0fCcvSPezJYEZYaMbfzEiabwB-JMJPz0YuMN49B0z2VaAiLoMsVElqGc9MQZl_dy-6z-ymx3tL0KlrYfBaZYX9JaYXaF29aVWr2XobDFq_ozBR3jy9_0HDlFjEh9yeWMTXu5yjsYiLxqsoHKB0zTxU3PEaem36HJFGHjmwA4T4zjt9F30WXuhqEzaq8JG0yxluwZLLt2Htrjog34bzh5KKetYkT4vKqnGTnJOHBUn1bAcey8jbWdKp26mMySAnZVkSWey4k_acu5OMMoL48eo-_pLzCfcuPF_9fOp0g6q_QpCykE0CyZkR1jDLhEspTZzJfHgSKhPbSDkuaRaHfcsNNZIp53wwkglHXeqUSpTlNt6DlXyUuwMgqUiZyiynIkYGrTSxsUAyQhlz1pdZcgjNel31W0mjoev7ZUONatCoBp-PaFTDIYh67fUf1qA90P974FmtKe3_Ezz86OduNB1rKiTDhJN6mf1ShfOZ-IHIoyeP_vezx7BOsSyi2J05gZXJ-9Sd-mBlYhqwfPEZNWC1ffly-wuf17fd-0Zho18Y_eoj |
link.rule.ids | 315,786,790,3525,4521,24144,27602,27957,27958,45620,45698,45714,45909 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB58gHoR329dQTw1NtnsK0cpSn1URCt4W7rZDbRIKraCXvzt7uRhEdGD1zAhy85k5pvdmW8AjhLhl2cjFxgfngMmeypQEZdBFqoktYxnpqDM79yI9gO7fOSPU9Cqe2GwrLLy_aVPL7x19aRZ7Wbzud9v3kdhorx5-viDhimTaZhFOI_zG04-JnUeIi4mr6J0gOI19VBR5DXw6vRJIo2868AREOK38PQb_CzC0PkSLFb4kZyWS1yGKZevwFynuiFfgePbkov6vUG6k9aqUYMck9sJS_X7KtyV0NtZ0qrnqYxIPydlXxKZHLmT0y_yTjLMCDqQJ_f2Q85n3GvwcH7WbbWDasBCkLKQjQPJmRHWMMuESylNnMk8PgmViW2kHJc0i8Oe5YYayZRzHo1kwlGXOqUSZbmN12EmH-ZuE0gqUqYyy6mIkUIrTWwskI1Qxpz1ZJZsQaPeV_1c8mjousBsoFENGtXgExKNatgCUe-9_mYO2nv6v188rDWl_Y-Ctx-93A1fR5oKyTDjpF5mo1Th10r8i0ikJ7f_-9kDmG93O9f6-uLmagcWKPZIFEc1uzAzfnl1ex65jM1-YZmfq5LpFQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reported+Challenges+in+Health+Technology+Assessment+of+Complex+Health+Technologies&rft.jtitle=Value+in+health&rft.au=Hogervorst%2C+Milou+A&rft.au=Vreman%2C+Rick+A&rft.au=Mantel-Teeuwisse%2C+Aukje+K&rft.au=Goettsch%2C+Wim+G&rft.date=2022-06-01&rft.eissn=1524-4733&rft.volume=25&rft.issue=6&rft.spage=992&rft_id=info:doi/10.1016%2Fj.jval.2021.11.1356&rft_id=info%3Apmid%2F35667787&rft.externalDocID=35667787 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-3015&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-3015&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-3015&client=summon |